Aug 13, 2020
Strata Oncology Announces Partnership to Broaden Enrollment in Mirati Therapeutics' Clinical Trial of MRTX849, a Novel KRAS G12C Selective Inhibitor
Aug 11, 2020
Cardiff Oncology Announces Second Quarter 2020 Results and Highlights
Jun 16, 2020
Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital
Jun 09, 2020
Cardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer as Follow-On to Fast Track Designation
Jun 05, 2020
Mirati Therapeutics to Present at 41st Annual Goldman Sachs Global Healthcare Conference
May 29, 2020
Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO
May 29, 2020
Amgen Presents New AMG 510 Clinical Data Across Multiple Solid Tumors During ASCO20 Virtual Scientific Program
May 28, 2020
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
May 19, 2020
Cardiff Oncology Announces Private Placement Investment by Board of Directors and Chief Executive Officer
May 18, 2020
Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations
May 15, 2020
Mirati Therapeutics To Present Preclinical Data From Investigational Pipeline Of Novel Therapeutics At 2020 American Association For Cancer Research Virtual Annual Meeting II
May 13, 2020
Amgen Showcases Oncology Pipeline At ASCO 2020
May 13, 2020
Cardiff Oncology Enters Agreement with PoC Capital to Fund Phase 2 Clinical Trial of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
May 07, 2020
Mirati Therapeutics Reports First Quarter 2020 Financial Results And Recent Corporate Updates
Apr 02, 2020
Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer
Apr 01, 2020
Trovagene Announces Acceptance of Phase 1b/2 KRAS-Mutated Metastatic Colorectal Cancer (mCRC) Trial Abstract for Presentation at the 2020 ASCO Annual Meeting
Feb 25, 2020
Mirati Therapeutics Reports Year-End 2019 Financial Results And Recent Corporate Updates
Feb 20, 2020
GeneTex Launches Novel Recombinant RAS (G12D Mutant) Antibody [HL10]
Feb 15, 2020
Mirati Therapeutics Announces Initial Data In Renal Cell Carcinoma From Ongoing Investigator Sponsored Clinical Trial Of Sitravatinib In Combination With Nivolumab At The 2020 ASCO Genitourinary Cancers Syposium
Jan 29, 2020
Trovagene Receives Approximately $1.45 Million From Exercise of Warrants